article

1. Cortical thickness and cognition in older people with multiple sclerosis..  Journal of neurology.  270:5223-5234. 2023
2. Predicting employment deterioration with the Processing Speed Test (PST) and SDMT in multiple sclerosis..  Multiple sclerosis (Houndmills, Basingstoke, England).  29:-. 2023
3. Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study..  Brain communications.  5:-. 2023
4. Antioxidant defense enzymes in multiple sclerosis: A 5-year follow-up study..  European journal of neurology.  30:2338-2347. 2023
5. Functional alteration due to structural damage is network dependent: insight from multiple sclerosis..  Cerebral cortex (New York, N.Y. : 1991).  33:6090-6102. 2023
6. Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse..  Multiple sclerosis (Houndmills, Basingstoke, England).  29:1033-1038. 2023
7. Metabolomic profiles in relapsing-remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study..  Metabolomics : Official journal of the Metabolomic Society.  19:-. 2023
8. Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis..  Journal of neurology.  270:3758-3769. 2023
9. Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study..  Multiple sclerosis and related disorders.  -. 2023
10. Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users..  Neurodegenerative disease management.  13:151-159. 2023
11. Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis..  Diagnostics (Basel, Switzerland).  13. 2023
12. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study..  Vaccines.  11. 2023
13. Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives..  Journal of neurology.  270:1120-1126. 2023
14. Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis..  Degenerative neurological and neuromuscular disease.  21-32. 2023
15. Fitts' Tapping Task as a New Test for Cognition and Manual Dexterity in Multiple Sclerosis: Validation Study..  Medicina (Kaunas, Lithuania).  59. 2022
16. Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC)..  Multiple sclerosis (Houndmills, Basingstoke, England).  29:753-756. 2022
17. Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis..  Neurology.  100:e911-e920. 2022
18. Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis..  Journal of neurology.  270:1266-1285. 2022
19. Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives..  Journal of neurology.  270:1095-1119. 2022
20. Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis..  Multiple sclerosis and related disorders.  -. 2022
21. Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic..  Multiple sclerosis and related disorders.  -. 2022
22. Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years..  Multiple sclerosis and related disorders.  -. 2022
23. Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study..  Multiple sclerosis and related disorders.  -. 2022
24. Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression..  Journal of neurology, neurosurgery, and psychiatry.  2022
25. Susceptibility networks reveal independent patterns of brain iron abnormalities in multiple sclerosis..  NeuroImage.  -. 2022
26. Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis..  Multiple sclerosis and related disorders.  -. 2022
27. A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis..  Multiple sclerosis journal - experimental, translational and clinical.  8:-. 2022
28. Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients..  European journal of neurology.  29:2299-2308. 2022
29. COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections..  Vaccines.  10. 2022
30. Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  32:910-919. 2022
31. Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis..  European radiology.  32:6468-6479. 2022
32. Editorial for "Paraspinal Muscle in Chronic Low Back Pain: Comparison Between Standard Parameters and Chemical Shift Encoding-Based Water-Fat MRI"..  Journal of magnetic resonance imaging : JMRI.  56:1609-1610. 2022
33. Editorial of Special Issue "Multiple Sclerosis: From Diagnostic Biomarkers to Imaging and Clinical Predictors"..  Diagnostics (Basel, Switzerland).  12. 2022
34. Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis..  Brain imaging and behavior.  16:1252-1259. 2022
35. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment..  CNS drugs.  36:45-59. 2021
36. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age..  Multiple sclerosis and related disorders.  -. 2021
37. MRI-based thalamic volumetry in multiple sclerosis using FSL-FIRST: Systematic assessment of common error modes..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  32:245-252. 2021
38. Functional network dynamics and decreased conscientiousness in multiple sclerosis..  Journal of neurology.  269:2696-2706. 2021
39. Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient..  Acta neurologica Belgica.  122:565-566. 2021
40. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study..  NeuroImage. Clinical.  -. 2021
41. Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives..  Neurodegenerative disease management.  11:329-340. 2021
42. Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis..  Journal of the neurological sciences.  -. 2021
43. Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient..  Multiple sclerosis (Houndmills, Basingstoke, England).  27:2291-2292. 2021
44. Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  31:995-1002. 2021
45. Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI..  NeuroImage. Clinical.  -. 2021
46. Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis..  Journal of neurology.  268:4796-4808. 2021
47. Staging and stratifying cognitive dysfunction in multiple sclerosis..  Multiple sclerosis (Houndmills, Basingstoke, England).  28:463-471. 2021
48. DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis..  NeuroImage. Clinical.  -. 2021
49. The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis..  Multiple sclerosis and related disorders.  -. 2021
50. Considering patient age when treating multiple sclerosis across the adult lifespan..  Expert review of neurotherapeutics.  21:353-364. 2021
51. Measuring Aqueduct of Sylvius Cerebrospinal Fluid Flow in Multiple Sclerosis Using Different Software..  Diagnostics (Basel, Switzerland).  11. 2021
52. Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?.  Journal of neurology.  268:2578-2588. 2021
53. Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes..  NeuroImage. Clinical.  -. 2021
54. Demographic, Clinical and Biochemical Characteristics of Pediatric Obesity: Interim Analysis of a Larger Prospective Study..  Folia medica.  62:746-752. 2020
55. Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis..  Multiple sclerosis and related disorders.  -. 2020
56. Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis..  Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.  33:294-300. 2020
57. Late onset multiple sclerosis is associated with more severe ventricle expansion..  Multiple sclerosis and related disorders.  -. 2020
58. Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis..  Frontiers in neurology.  -. 2020
59. Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study..  Journal of magnetic resonance imaging : JMRI.  53:731-739. 2020
60. Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis..  Diagnostics (Basel, Switzerland).  10. 2020
61. High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis..  Journal of the neurological sciences.  -. 2020
62. Long-term drug treatment in multiple sclerosis: safety success and concerns..  Expert opinion on drug safety.  19:1121-1142. 2020
63. Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption..  Journal of neurology.  268:169-177. 2020
64. Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients..  Frontiers in neurology.  -. 2020
65. Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis..  Multiple sclerosis and related disorders.  -. 2020
66. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis..  Journal of clinical lipidology.  14:675-684.e2. 2020
67. Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study..  Neurology(R) neuroimmunology & neuroinflammation.  7. 2020
68. Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  30:523-530. 2020
69. Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  30:342-350. 2020
70. MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis..  Expert review of neurotherapeutics.  20:821-834. 2020
71. Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study..  Multiple sclerosis and related disorders.  -. 2020
72. Use of patient-reported data in determining factors contributing to internal jugular vein stenosis outcomes..  Annals of translational medicine.  8:-. 2020
73. Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident case-control study..  Clinical nutrition (Edinburgh, Scotland).  39:3402-3407. 2020
74. Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls..  Neurobiology of aging.  84-92. 2020
75. Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy..  Fluids and barriers of the CNS.  17:-. 2020
76. Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective..  Vaccines.  8. 2020
77. Recovery of cognitive function after relapse in multiple sclerosis..  Multiple sclerosis (Houndmills, Basingstoke, England).  27:71-78. 2020
78. Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives..  Patient related outcome measures.  373-384. 2019
79. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis..  Journal of neurology.  267:802-811. 2019
80. Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders..  CNS drugs.  33:1073-1086. 2019
81. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study..  Multiple sclerosis (Houndmills, Basingstoke, England).  26:1670-1681. 2019
82. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis..  Radiology.  293:424-433. 2019
83. Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis..  Journal of vascular research.  57:16-23. 2019
84. Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis..  Human brain mapping.  40:5231-5241. 2019
85. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study..  Annals of clinical and translational neurology.  6:1757-1770. 2019
86. Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis..  Multiple sclerosis (Houndmills, Basingstoke, England).  26:1433-1436. 2019
87. High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?.  Journal of clinical lipidology.  13:654-663.e1. 2019
88. No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years..  BMC neurology.  19:-. 2019
89. Epidemiology and treatment of multiple sclerosis in elderly populations..  Nature reviews. Neurology.  15:329-342. 2019
90. Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings..  Neurodegenerative disease management.  9:149-172. 2019
91. Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study..  Journal of lipid research.  60:1190-1198. 2019
92. Aging and Brain Atrophy in Multiple Sclerosis..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  29:527-535. 2019
93. Cognitive Profiles of Aging in Multiple Sclerosis..  Frontiers in aging neuroscience.  -. 2019
94. Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities..  Expert review of neurotherapeutics.  19:445-458. 2019
95. Coagulation Pathways in Neurological Diseases: Multiple Sclerosis..  Frontiers in neurology.  -. 2019
96. in vivo.  Neural regeneration research.  14:373-386. 2019
97. Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study..  Journal of neurology.  266:866-875. 2019
98. Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study..  Multiple sclerosis (Houndmills, Basingstoke, England).  26:322-332. 2019
99. Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients..  Multiple sclerosis (Houndmills, Basingstoke, England).  26:201-209. 2019
100. Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study..  Current neurovascular research.  16:215-223. 2019
101. Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?.  Thrombosis and haemostasis.  119:175-178. 2018
102. Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures..  Multiple sclerosis and related disorders.  298-304. 2018
103. Interferon β for Multiple Sclerosis..  Cold Spring Harbor perspectives in medicine.  8. 2018
104. Plasma levels of soluble NCAM in multiple sclerosis..  Journal of the neurological sciences.  36-41. 2018
105. Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage..  Journal of the neurological sciences.  128-134. 2018
106. Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?.  Clinical autonomic research : official journal of the Clinical Autonomic Research Society.  29:329-338. 2018
107. Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition..  Multiple sclerosis (Houndmills, Basingstoke, England).  25:1243-1254. 2018
108. Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients..  Multiple sclerosis and related disorders.  37-42. 2018
109. Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  28:490-495. 2018
110. Jugular Venous Flow Quantification Using Doppler Sonography..  Ultrasound in medicine & biology.  44:1762-1769. 2018
111. White matter tract network disruption explains reduced conscientiousness in multiple sclerosis..  Human brain mapping.  39:3682-3690. 2018
112. Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study..  Journal of alternative and complementary medicine (New York, N.Y.).  24:596-602. 2018
113. Neck Vessel Cross-Sectional Area Measured with MRI: Scan-Rescan Reproducibility for Longitudinal Evaluations..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  28:48-56. 2017
114. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis..  Expert opinion on biological therapy.  17:1163-1172. 2017
115. Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis..  Current neurovascular research.  14:266-273. 2017
116. Use of natalizumab in multiple sclerosis: current perspectives..  Expert opinion on biological therapy.  16:1151-62. 2016
117. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine..  Expert review of neurotherapeutics.  16:777-93. 2016